Bioxytran, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.bioxytraninc.com
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Bioxytran Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05733780
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
Phase 3
- Conditions
- COVID-19 PandemicCOVID-19 Respiratory InfectionSARS-CoV2 InfectionCytokine Release SyndromeCOVID-19
- Interventions
- Drug: PLACEBO
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Bioxytran Inc.
- Target Recruit Count
- 408
- Registration Number
- NCT05096052
© Copyright 2025. All Rights Reserved by MedPath